arrow
R

Richard LeBlanc

hopital maisonneuve-rosemont
H指数:32
被引数:8,250

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Outcomes In Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

t(11;14)骨髓瘤患者的真实世界结局:一项基于加拿大骨髓瘤研究组国家临床数据库的匹配比较研究

2025-11-040
PRE
Salvage autologous stem cell transplantation outcomes and the use of maintenance in relapsed multiple myeloma: Real world evidence from the Canadian Myeloma Research Group Database

自体干细胞移植的挽救性治疗结果及在复发多发性骨髓瘤中维持治疗的应用:来自加拿大骨髓瘤研究组数据库的真实世界证据

2025-10-310
PRE
Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

多发性骨髓瘤患者接受二线治疗的治疗模式与结局:加拿大骨髓瘤研究组(CMRG)分析

2025-02-270
PRE
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients
2025-01-010
OAAI
Tandem Autologous Stem Cell Transplantation Does Not Benefit fi t High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database
2024-09-011
PRE
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
2023-12-083
OAAI
Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
2023-09-056
OAAI
Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis

含达雷妥尤单抗的方案在接受来那度胺维持治疗的多发性骨髓瘤进展患者中的疗效: 回顾性分析

2022-02-187
OAAI
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
2021-11-2025
OA
Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial
2021-04-1213
OAAI